Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Prostate-specific antigen in clinical practice.

Stacy Loeb1, William J Catalona

  • 1Department of Urology, Georgetown University School of Medicine, Washington, DC, United States.

Cancer Letters
|January 30, 2007
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Diagnosis and Staging of Patients with Prostate Cancer: Report from the 2025 Advanced Prostate Cancer Consensus Conference (APCCC) Diagnostics.

European urology·2026
Same author

Availability, quality, and understandability of English and Spanish-language YouTube content on PSMA PET imaging for prostate cancer.

Clinical imaging·2026
Same author

Balancing Cure and Quality of Life: Navigating Functional Outcomes in Localized Prostate Cancer.

American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting·2026
Same author

The burden of Peyronie's disease on the female partner: a qualitative study.

The journal of sexual medicine·2026
Same author

Intimacy After Diagnosis: Navigating Sexual Health Conversations and Disparities Among Cancer Survivors.

The American journal of hospice & palliative care·2026
Same author

Evolving strategies in prostate cancer: Emerging approaches and unmet needs from the Bridging the Gaps in Prostate Cancer expert panel.

Cancer·2026
Same journal

Stress-adapted cancer-associated fibroblasts as mediators of immunosuppression and therapy resistance.

Cancer letters·2026
Same journal

Aldo-keto Reductase Family 1 Member C3 Suppresses Glioma Progression via Inhibiting Prostaglandin D2-Dependent RhoA/ROCK Signaling.

Cancer letters·2026
Same journal

Immunotherapy-based combination remodels the immunosuppressive microenvironment and enhances efficacy in advanced SMARCA4-deficient non-small cell lung cancer.

Cancer letters·2026
Same journal

Early-onset lung cancer: etiologic heterogeneity, genomic features, and age-informed clinical management.

Cancer letters·2026
Same journal

Talazoparib engages innate immune activation via PARP trapping-dependent cGAS/STING activation in Ewing Sarcoma.

Cancer letters·2026
Same journal

Corrigendum to "Elevated MMP10/13 mediated barrier disruption and NF-κB activation aggravate colitis and colon tumorigenesis in both individual or full miR-148/152 family knockout mice" [Cancer Lett. (2022) 31 529 53-69].

Cancer letters·2026
See all related articles

Prostate-specific antigen (PSA) screening aids in early prostate cancer detection and monitoring. Advanced PSA measurements improve specificity, reducing metastatic disease and mortality rates.

Area of Science:

  • Urology
  • Oncology
  • Biochemistry

Background:

  • Prostate cancer is commonly diagnosed using digital rectal examination (DRE) and serum prostate-specific antigen (PSA) tests in the US.
  • Serum PSA levels correlate with cancer risk, aggressiveness, and treatment outcomes, and are vital for monitoring recurrence.
  • Current PSA testing has limitations in specificity, prompting debate on its optimal clinical use.

Purpose of the Study:

  • To review the history and evidence behind various prostate-specific antigen (PSA) measurements for prostate cancer screening.
  • To discuss adjuncts to PSA testing that enhance its specificity and clinical utility.

Main Methods:

  • Review of historical data and clinical evidence related to PSA screening and its variations.
  • Analysis of the impact of PSA screening on prostate cancer detection and mortality rates.

Related Experiment Videos

Main Results:

  • Widespread PSA screening has led to a significant reduction in metastatic prostate cancer presentation since 1985-89.
  • A notable decrease in age-adjusted prostate cancer mortality rates was observed through 2003.
  • Variations like PSA isoforms, PSA density, and PSA velocity offer improved diagnostic accuracy.

Conclusions:

  • PSA screening, particularly with enhanced measurements, has demonstrably reduced prostate cancer mortality and late-stage diagnoses.
  • Continued research and application of advanced PSA metrics are crucial for optimizing prostate cancer management.